Good Morning Investors!!! Stock futures are a bit brighter, but the bond market still has the remote, with the 10-year Treasury yield hovering near 4.07% ahead of the Federal Open Market Committee minutes at 2:00 PM ET. Before lunch, we get a heavy dose of “real economy” data at 8:30 AM ET with housing starts, permits, and durable goods (update in “On the Calendar” section), plus industrial production at 9:15 AM ET. In company news, Danaher’s nearly $10 billion move for Masimo is a big reminder that deals can move stocks fast, even when the broader market feels calm. Keep an eye on yields after the minutes, because if they jump, today’s early optimism can fade quickly.
|
Key Market Drivers
Tech mood turns brighter before the bell: U.S. stock futures were higher early Wednesday, with S&P 500 futures up 0.57% and Nasdaq futures up 0.65%. That follows Tuesday’s late-day save, when the S&P 500 closed up 0.1% after being down as much as 0.9%. Nvidia was up 1.9% premarket after it landed a deal to sell Meta artificial intelligence (AI) chips. Tech drives the indexes, so the next tell is the Federal Reserve (Fed) minutes at 2:00 PM ET and whether Palo Alto Networks’ 7.2% drop stays contained. Bonds are back in the driver’s seat: The 10-year Treasury yield rose to 4.07%, about 2 basis points higher, after touching 4.02% on Tuesday, a two-and-a-half-month low. Traders are bracing for the Fed minutes later today. Traders are pricing a June cut, with odds near 63%, and the Fed minutes today can shift that. Higher yields can pinch stock valuations, so the next gut-check is Friday’s Personal Consumption Expenditures (PCE) Price Index (Fed’s preferred inflation gauge) and Gross Domestic Product (GDP) at 8:30 AM ET. 
10 Year Treasury Yield, Feb 18, 2026
Oil steadies, but the map still matters: Oil is higher in early Wednesday trading after Tuesday’s slide, with Brent around $68.20 a barrel and WTI near $63.06. Brent fell about 1.8% Tuesday and WTI slid about 0.9% as traders weighed progress in U.S.-Iran talks against ongoing supply-risk headlines. That balance reflects two stories pulling in opposite directions: diplomacy with Iran that could ease supply fears, and fresh reminders that the Strait of Hormuz is still a choke point. Oil matters because it can nudge inflation and the Fed, so the next check is U.S. inventory data over the next 24 to 48 hours. Europe hits a record while Asia blinks awake: European stocks rose again, with the STOXX 600 up 0.8% to a record 626.36. Defense shares led, and BAE Systems gained 2.6% after upbeat results and a record £83.6 billion backlog, while reports of a possible ECB leadership shakeup swirled. In Asia, Japan’s Nikkei rose 1% after exports jumped 16.8% from a year ago. A firmer global tone can lift risk appetite, but the next check is whether the ECB leadership rumor fades or grows, and how the euro and US futures react. |
|
Biotech
Biotech is the lab-coat corner of the market, not just weight-loss drugs. One study can flip a stock in a day. The SPDR S&P Biotech ETF (XBI) is down about 0.5% over the past month but it’s up nearly 37% over the past year.
Investors are juggling lower yields with a tougher rulebook. Lower rates can make long-term growth stories look more valuable, but stricter reviews can slow new products and push timelines out. Food and Drug Administration (FDA) headlines are part of the noise right now. Term: Phase 3 trial. Large study that often decides FDA approval.
Regeneron (REGN):
Regeneron makes antibody-based medicines, led by Dupixent for eczema and other inflammatory diseases. Its edge is a repeatable antibody “platform” that can feed a pipeline. Last quarter, Dupixent sales rose 34% to about $4.9 billion, while its eye-drug business faced more competition.
Moderna (MRNA):
Moderna uses messenger ribonucleic acid (mRNA) to design vaccines and new therapies. The platform is built for speed. It posted fourth-quarter revenue of $678 million and a $2.11 per share loss, and the FDA has reversed course and will review Moderna’s modified flu-vaccine application, with a decision expected by Aug. 5, 2026.
Roche (RHHBY):
Roche is a Swiss healthcare giant that sells both medicines and diagnostics, which can be an edge in cancer care. In 2025 it reported group sales of about 61.5 billion Swiss francs. Currency moves are the swing factor, since they can change how overseas growth looks in U.S. terms.
InvestorsGrow Takeaway:
Watch the 10-year Treasury yield, since rising yields can cool demand for “profits later” sectors like biotech. Two KPIs analysts track are the FDA decision calendar and cash runway (how long a company can fund research without new money), and a red flag is a wave of stock offerings that hints at cash stress. If yields rise while fundraising jumps, expect smaller biotechs to wobble first.
Danaher Corporation (DHR)
Danaher makes lab and hospital tools that help run tests and track samples. It is the backstage crew of healthcare: you do not see it, but the show stops without it.
Danaher agreed to buy Masimo for $180 a share in cash, about $9.9 billion including debt, to add patient monitors like pulse oximeters. Danaher slid almost 3% to about $206 in Tuesday premarket trade (as of 8:05 AM ET), while Masimo jumped about 34% to $174.69 as deal math kicked in.
Over the five years ended Dec. 31, 2024, Danaher delivered about +72% total return (dividends reinvested), but it was about -1% over the year ended Dec. 31, 2024. That flat stretch hints investors want proof that growth is coming back.
The first reaction looks like surprise, not panic. Danaher’s sweet spot is life-science tools and diagnostics, so diving into bedside monitoring pushes it toward tougher turf, with big rivals like Medtronic. Even a $150 billion buyer can feel integration risk, especially with higher rates.
The key number is the expected earnings per share (EPS) (profit per share) bump: +$0.15 to +$0.20 in the first full year after closing, and about +$0.70 by year five. If that shows up, it can ease worries that “synergies” (cost cuts or sales boosts from combining) are wishful thinking.
Watch the regulatory path and any early detail on cost savings, since the companies target a second-half 2026 close. If Danaher keeps margins steady as it folds Masimo in, the market will likely relax; if costs spike, the story gets harder.
InvestorsGrow Takeaway:
Danaher is trying to buy its way into a new stream of hospital demand. If Masimo brings steadier repeat sales and the expected EPS bump shows up, confidence can rebuild. If integration drags, competition and hospital price pushback become the headache. Watch whether that year-one EPS lift starts to look doable.
